Evidence map›Paper›PMID 39350402›Full record

ReviewCurrent molecular medicine2025

Role of Nrf2 in Epilepsy Treatment.

Maryam Azadmanesh, Tahereh Farkhondeh, Mohammad Sadra Harifi-Mood, Michael Aschner, Fariborz Samini, Saeed Samarghandian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam AzadmaneshDivision of Pharmacology and Toxicology, Department of Basic Sciences, Faculty of Veterinary Medicine, University of Shiraz, Shiraz, Iran.
Tahereh FarkhondehGeriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Mohammad Sadra Harifi-MoodGeriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Forchheimer 209 1300 Morris Park Avenue, Bronx, NY, USA.
Fariborz SaminiNeuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Saeed SamarghandianDepartment of Medical Physiology, School of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress is a consequence of the disruption of the balance between the generation of reactive nitrogen and oxygen species and the biological system's ability to neutralize those reactive products. Oxidative stress is involved in the generation of many disorders, including epilepsy, which is a prevalent chronic neurological disease that affects the lives of millions of people around the world. Epilepsy is characterized by unforeseeable and repeated seizures that can be very disturbing. Studies have reported that oxidative stress occurs before and after seizures. A transcription factor named Nuclear factor erythroid-derived 2-related factor 2 (Nrf2) controls genes related to the induction of oxidative stress and defends cells against oxidative stress. The Nrf2 protein has seven different domains, ranging from Neh1 to Neh7. Each domain is responsible for a distinctive function of this protein. Keap1 binds to Nrf2, but during oxidative stress, Nrf2 detaches from the Keap1 protein, moves to the nucleus, and binds to DNA. The result of this translocation and binding is the initiation of transcription of detoxifying genes to control the harmful effects of oxidative stress. There is some evidence of oxidative stress involvement in epilepsy. In this review, we have listed potential Nrf2-related therapeutic targets for treating and controlling epilepsy, such as Berberis alkaloids, pentoxifylline, lovastatin, progesterone, and chrysin nanoparticles. These activators were tested in animals (in vivo) and cells (in vitro), and most of these experiments showed promising results in different epilepsy models. Finally, the results have suggested that the activation of Nrf2 can be an option for controlling epilepsy.

Indexed as

EpilepsyNF-E2-Related Factor 2AnimalsHumansOxidative StressNFE2L2 protein, humanNF-E2-Related Factor 2aura.epilepsyNrf2oxidative stressoxygen speciesseizures

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.